MacroGenics | MGNX - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.72B 1.99B 2026-06
Amgen USD 4.61B 777M 2026-06
AstraZeneca USD 3.16B 3.95B 2026-06
Biogen USD -243.8M 758.1M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Daiichi Sankyo JPY 85.1B 4.44B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Genmab DKK 407M 182M 2026-06
Geron USD -236K 10.55M 2026-03
Gilead Sciences USD 3.85B 1.17B 2026-06
J&J USD 7.48B 860M 2026-06
Karyopharm Therapeutics USD -26.76M 8.92M 2026-03
MacroGenics USD -33.44M 21.34M 2026-03
Merck USD 840M 2.72B 2026-06
Pfizer USD 667M 4.32B 2026-06
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Xencor USD -36.6M 41.26M 2026-06